Biomarkers for disease progression and therapy evaluation
Readily Available MRI techniques:
- Structure analysis (volumetric and morphometry)
- Microstructural MRI (diffusion tensor, kurtosis, and fixel-based)
- Brain functional connectivity (Functional connectivity, CAPs and QPPs)
- Brain functional activity (stimulus-based and pharmaco-based fMRI)
- Susceptibility weighted Imaging (SWI and QSM)
- Cerebral Blood perfusion (CBF) and volume (CBV) using ASL
- Brain clearance (invasive and non-invasive glymphatic clearance)
- Manganese enhanced MRI (MEMRI)
- Magnetic resonance spectroscopy (MRS)
- Metabolic rate of O2 consumption; 31P MRS for energy metabolism
- Fluor-MRI; Magnetization transfer / Glutamate CEST
Readily Available PET tracers
- Dopamine D1 Receptors (D1R) using [11C]SCH23390
- Dopamine D2/3 Receptors (D2/3R) using [11C]Raclopride
- Phosphodiesterase 10A (PDE10a) using [18F]MNI-659
- Pre-synaptic density (SV2A) using [18F]SynVesT-1
- Neuroinflammation (Translocator protein, TSPO) using [18F]PBR111
- Glucose metabolism using [18F]FDG
- mGluR5 using [11C]ABP688 or [18F]FPEB
- mHTT aggregates using [11C]CHDI-180R, [18F]CHDI-650, others…
- Beta-amyloid aggregates using [18F]AV-45 or [11C]PiB